- Category
- Small (2022-23)
- Udyam number
- UDYAM-TS-20-0002578

About Indu Drugs Private Limited
Data last updated:
Indu Drugs Private Limited is a private limited company based in Hyderabad, Telangana, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 04 April 2012 and has been in existence for over 14 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U85191TG2012PTC080169. Its GSTIN is 36AACCI8823L1Z7 (Telangana). The company holds 3 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹4.4 Cr and a paid-up capital of ₹4.39 Cr. It is led by directors including Talasila Hari Prasada Rao (Managing Director) and Sai Kumar Talasila (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 5 – 5 – 35/278 & 279 Prashanthi Nagar Ida Kukatpally, Hyderabad, Telangana, India – 500072.
As per the financials filed for FY 2025, the company reported a revenue of ₹18.78 Cr, a decline of 10% compared to the previous year. For the same year it recorded a net profit of ₹22.31 Lakh (net margin 1.2%) and EBITDA of ₹63.98 Lakh (EBITDA margin 3.4%). Revenue has grown at a compounded annual rate (CAGR) of 8% over three years and 1% over five years.
The company has about 64 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Indu Drugs. As per MCA filings, the company has open charges of ₹4 Cr and satisfied charges of ₹2.9 Cr on record. Court records list 6 cases involving the company, including 1 filed by the company and 5 filed against it.
Indu Drugs Private Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-TS-20-0002578). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website indudrugs.com.
Company details
CIN history
Indu Drugs has one previous CIN (Corporate Identification Number): U85191AP2012PTC080169. The current CIN is U85191TG2012PTC080169, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U85191TG2012PTC080169 | Current |
| U85191AP2012PTC080169 | Previous |
Recognitions & Rankings of Indu Drugs
Contact details
Indu Drugs Private Limited's registered office is in Hyderabad, Telangana. Its website is indudrugs.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address5 – 5 – 35/278 & 279 Prashanthi Nagar Ida Kukatpally, Hyderabad, Telangana, India – 500072
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Indu Drugs Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Indu Drugs operates one associated brand: Indu Drugs. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufacturer of formulations | indudrugs.com |
Business activity
The main business activity of Indu Drugs is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Indu Drugs Private Limited, buy the company report.
Financials of Indu Drugs Private Limited
FY 2025 filings availableIndu Drugs Private Limited reported revenue of ₹18.78 Cr (down 10% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue fell 10% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 1%. EBITDA fell 51% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹63.98 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹22.31 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 3.4% | ||||
| Net Profit Margin | 1.2% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Indu Drugs Private Limited, buy the company report.
Board of directors of Indu Drugs Private Limited
Indu Drugs has 3 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sai Kumar Talasila | Whole-Time Director | 23 Nov 2016 | 9 Years 11 Months | Current |
| Venkateswara Rao Talasila Also directs: Blooming Spaces LLP | Whole-Time Director | 09 Nov 2013 | 12 Years 11 Months | Current |
| Talasila Hari Prasada Rao | Managing Director | 04 Apr 2012 | 14 Years 6 Months | Current |
Peer comparison
Indu Drugs Private Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Isera Biological Limited | ₹18.94 Cr (FY 2025) | 83.0% | Pune, Maharashtra, India | |||
| Kee Pharma Limited | ₹18.89 Cr (FY 2025) | 3.0% | New Delhi, Delhi, India | |||
| Santiago Life Sciences Private Limited | ₹18.88 Cr (FY 2024) | 5.0% | Jabalpur, Madhya Pradesh, India | |||
| Indu Drugs Private Limitedthis company | ₹18.78 Cr (FY 2025) | ₹22.31 Lakh | 1.2% | -10.0% | 64 | Hyderabad, Telangana, India |
| Gulkas Pharma Pvt Ltd | ₹18.78 Cr (FY 2025) | 21.0% | Kalol, Gujarat, India | |||
| Medilife Impex Private Limited | ₹18.66 Cr (FY 2025) | 3.0% | Hingna, Maharashtra, India |
To see the full peer comparison of Indu Drugs Private Limited, buy the company report.
Auditor
Indu Drugs Private Limited is audited by K. R. BAPUJI & CO. for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| K. R. BAPUJI & CO. | FY 2024 | 000395S |
Shareholding
The shareholding of Indu Drugs Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Indu Drugs Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 15 Jul 2023 | 100753475 | Hdfc Bank Limited | ₹4 Cr | Open | |
| 26 Dec 2018 | 100243343 | Axis Bank Limited | ₹50 Lakh | Satisfied | |
| 01 Oct 2015 | 10595585 | Canara Bank | ₹1.4 Cr | Satisfied | |
| 05 Dec 2012 | 10389771 | State Bank of India | ₹1 Cr | Satisfied |
To see the full charge records of Indu Drugs Private Limited, buy the company report.
Total charge records: 4 View all charges
Legal cases
Indu Drugs Private Limited has 6 court cases on record: 1 filed by Indu Drugs, 5 filed against it. All cases are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 6 | 5 | 0 |
Cases on record (4 of 6)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court, TAMIL NADU | Appeal | Filed against the company by Wockhardt Limited | Disposed |
| High Court, TAMIL NADU | Original application | Filed against the company by Wockhardt Limited | Disposed |
| High Court, TAMIL NADU | Appeal | Filed by the company against Wockhardt Limited | Disposed |
| High Court, TAMIL NADU | Civil suit | Filed against the company by Wockhard Limited | Disposed |
To see the full case history of Indu Drugs Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Indu Drugs Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Indu Drugs Private Limited has a workforce of 64 employees on its EPFO records as of Feb 28, 2025, across 1 active EPFO establishment.
GST
Indu Drugs has 3 GST registrations: 1 active and 2 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AACCI8823L1Z7 | Telangana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Indu Drugs Private Limited, buy the company report.
Recent activity
Indu Drugs Private Limited has 8 board changes on record since 2012: 3 appointments and 5 cessations. The latest: Lakshmi Kumari Talasila ceased to be Additional Director on 01 Apr 2018.
8 earlier events are in the company report.
Frequently asked questions
Indu Drugs is an active private limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 04 April 2012 (14+ years old) and is registered under CIN U85191TG2012PTC080169.
Indu Drugs has 3 current directors:
- Talasila Hari Prasada Rao - Managing Director
- Sai Kumar Talasila - Whole-Time Director
- Venkateswara Rao Talasila - Whole-Time Director
The latest financial statements of Indu Drugs on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Indu Drugs is 36AACCI8823L1Z7, registered in Telangana. The company has 3 GST registrations in all, of which 1 is active and 2 are cancelled or inactive.
The CIN (Corporate Identification Number) of Indu Drugs is U85191TG2012PTC080169. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Indu Drugs has 6 court cases on record: 1 filed by the company and 5 filed against it.
Indu Drugs was incorporated on 04 April 2012, making it 14+ years old. It is registered with the Registrar of Companies, Hyderabad.
The peers of Indu Drugs by revenue are Isera Biological Limited, Kee Pharma Limited, Santiago Life Sciences Private Limited, Gulkas Pharma Pvt Ltd, Medilife Impex Private Limited, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Lakshmi Kumari Talasila ceased to be Additional Director on 01 Apr 2018. Rajeswari Talasila ceased to be Director on 01 Apr 2018. Sai Kumar Talasila ceased to be Director on 01 Apr 2018. Indu Drugs has 8 board changes on record in total.
Yes, Indu Drugs is registered as a small enterprise under Udyam registration (number: UDYAM-TS-20-0002578).
Indu Drugs can be reached through the website indudrugs.com. Its registered office is in Hyderabad, Telangana, India.

